SCHEMBL279924

SCHEMBL279924

Cc1ccc(C(=O)CNc2ccncn2)n1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.40
CYP3A4 P08684 2/20 0.35
CYP2D6 P10635 2/20 0.35
CYP2C9 P11712 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
HTT P42858 1/20 0.35
GRIN2B Q13224 2/20 0.34
P2RX7 Q99572 1/20 0.34
GSK3B P49841 5/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA4 P43681 1/20 0.33
EPHX2 P34913 1/20 0.32
RXRA P19793 1/20 0.32
GRIN1 Q05586 1/20 0.32
FAAH O00519 2/20 0.32
MKNK1 Q9BUB5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL280148 0.72 ADORA2A (0.43) NAMPTCYP3A4CYP2D6CYP2C9SMN1; SMN2
SCHEMBL2401814 0.72 P2RX7 (0.44) CYP3A4CYP2D6CYP2C9SMN1; SMN2CYP1A2
SCHEMBL4419704 0.71 SMN1; SMN2 (0.48) CYP3A4CYP2D6CYP2C9SMN1; SMN2CYP1A2
SCHEMBL280375 0.71 GSK3B (0.47) NAMPTCYP3A4CYP2D6CYP2C9SMN1; SMN2
SCHEMBL4466178 0.70 P2RX7 (0.47) CYP3A4CYP2D6CYP2C9SMN1; SMN2CYP1A2
SCHEMBL6259328 0.69 SMN1; SMN2 (0.40) CYP3A4CYP2D6CYP2C9SMN1; SMN2CYP1A2
SCHEMBL10784324 0.65 ALDH1A1 (0.40) NAMPTCYP3A4CYP2D6SMN1; SMN2CYP1A2
SCHEMBL11862008 0.64
SCHEMBL7511801 0.63 CYP2C9 (0.46) CYP3A4CYP2D6CYP2C9SMN1; SMN2CYP1A2
SCHEMBL8489612 0.63 TOP2A (0.48) NAMPTCYP3A4CYP2D6CYP2C9SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL NAMPT 1398/4885CYP3A4 3149/4885CYP2D6 2749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.